UROMITEXAN 100 MG
MESNA : 100 MG · DIN 02241411 · BAXTER CORPORATION
Health Canada status: MARKETED
What is UROMITEXAN?
UROMITEXAN 100 MG contains MESNA : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02241411, held by BAXTER CORPORATION, supplied as SOLUTION for ORAL ; INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 16-Jan-2004. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is UROMITEXAN used for?
UROMITEXAN (mesna) is indicated for the reduction and prevention of urinary tract toxicity (hemorrhagic cystitis) of oxazaphosphorines.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02241411 |
|---|---|
| Brand name | UROMITEXAN |
| Generic / active ingredient | MESNA : 100 MG |
| Manufacturer | BAXTER CORPORATION |
| Strength | 100 MG |
| Dosage form | SOLUTION |
| Route of administration | ORAL ; INTRAVENOUS |
| Schedule | Prescription |
| ATC code | V03AF01 MESNA |
| AHFS class | 91:04.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Jan-2004 |
| Original market date | 2001-03-06 00:00:00 |
How is it stored and handled?
STORAGE AND STABILITY
How is it supplied?
1 g, 5 g multi-dose vials
Is MESNA in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by FRESENIUS KABI CANADA LTD, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code V03AF01 MESNA. 3 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MESNA FOR INJECTION | 100 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02244931 |
| UROMITEXAN | 100 MG | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02371839 |
| UROMITEXAN INJ 100MG/ML | 100 MG | LIQUID | BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB | CANCELLED POST MARKET | DIN 00797219 |
Who else supplies MESNA worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MESNA appears in 27 registered pack listings across 9 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.